| Identification | Back Directory | [Name]
Ixazomib citrate (USAN) | [CAS]
1239908-20-3 | [Synonyms]
MLN9708（b）
Ixazomib citrat
Esazomib citrate
Lxazomib Citrate
Ixazomib Impurity N
Ixazomib Impurity 19
Ixazomib citrate (USAN)
Ixazomib citrate(MLN9708)
IXAZOMIB CITRATE;MLN 9708;MLN-9708
IXAZOMIB; MLN-9708;MLN9708;MLN 9708
Ixazomib Impurity 23 (Ixazomib Citrate)
Ixazomib citrate (USAN)（For R & D only）
2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
2-[(1R)-1-[[2-[(2,5-Dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid
(R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid
1,3,2-Dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-
2-[4-(carboxymethyl)-2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolan-4-yl]acetic acid
MLN 9708 / Ixazomib citrate / 1,3,2-Dioxaborolane-4,4-diacetic acid, 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-
(R)-2,2'-(2-(1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-5-oxo-1,3,2-dioxaborolane-4,4-diyl)diacetic acid compound with 2-hydroxypropane-1,2,3-tricarboxylic acid (1:1) | [Molecular Formula]
C20H23BCl2N2O9 | [MDL Number]
MFCD29767859 | [MOL File]
1239908-20-3.mol | [Molecular Weight]
517.12 |
| Chemical Properties | Back Directory | [density ]
1.47±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO:100.0(Max Conc. mg/mL);193.38(Max Conc. mM)
Ethanol:100.0(Max Conc. mg/mL);193.38(Max Conc. mM) | [form ]
Solid | [pka]
3.59±0.10(Predicted) | [color ]
White to off-white | [InChIKey]
MBOMYENWWXQSNW-AWEZNQCLSA-N | [SMILES]
O1C(=O)C(CC(O)=O)(CC(O)=O)OB1[C@@H](NC(CNC(=O)C1=CC(Cl)=CC=C1Cl)=O)CC(C)C |
| Hazard Information | Back Directory | [Uses]
Ixazomib Citrate is a reversible boronic acid proteasome inhibitor. | [Definition]
ChEBI: A glycine derivative that is the amide obtained by formal condensation of the carboxy group of N-(2,5-dichlorobenzoyl)glycine with the amino group of 2,2'-{2-[(1R)-1-amino-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diy
}diacetic acid. A prodrug for ixazomib that is used in combination therapy for treatment of multiple myeloma. | [in vivo]
Ixazomib citrate (MLN9708; 11 mg/kg) significantly inhibits MM tumor growth and prolongs survival in the human plasmacytoma MM.1S xenograft mouse model. The blood chemistry profiles of Ixazomib-treated mice show normal levels of creatinine, hemoglobin, and bilirubin. Ixazomib dramatically increases the number of cleaved-caspase-3 positive cells of the xenograft model[2]. |
|
|